Druggability & Clinical Context
Druggability
Undruggable
Score: 0.21
Target Class
Structural Protein
Druggability Analysis
Structural Tractability0.30
Key Metrics
PDB Structures:
0
Known Drugs:
4
Approved:
0
In Clinical Trials:
2
Drug Pipeline (4 compounds)
1 Preclinical
Druggability Rationale: Despite its critical role in neuronal plasticity, GAP43 remains challenging to drug directly due to its intrinsically disordered protein structure and membrane-associated localization. While preclinical agents like PACAP and BDNF show promise in modulating GAP43-related pathways, the lack of a well-defined binding pocket and the protein's complex phosphorylation-dependent mechanisms make traditional small molecule targeting difficult. Future druggability strategies may require innovative approaches such as phosphorylation mimetics, protein engineering, or indirect modulators that enhance GAP43 expression or membrane translocation in neurodegenerative contexts.
Mechanism: Drugs targeting GAP43 would enhance axonal growth cone formation and synaptic plasticity by promoting phosphorylation or membrane translocation of GAP43, thereby facilitating neurite outgrowth and synapse formation. Alternatively, agents could upregulate GAP43 expression to restore neuronal connectivity and compensate for age-related decline in neurodegenerative conditions.
Drug Pipeline (4 compounds)
1 Preclinical
Known Drugs:Pituitary Adenylyl Cyclase-Activating Peptide (PACAP) (preclinical) — Neuronal growth and synaptic plasticity enhancement
BDNF (Brain-Derived Neurotrophic Factor) (phase1) — Neurodegenerative diseases, traumatic brain injury
Chondroitinase ABC (research) — Axonal regeneration, spinal cord injury
NSF127 (phase2) — Alzheimer's disease, cognitive decline
Structural Data:PDB —AlphaFold ✓Cryo-EM —
Selectivity & Safety Considerations
GAP43 selectivity is less challenging than typical enzyme targets due to its structural protein classification with no enzymatic active sites; however, off-target effects remain a concern when using indirect modulators (e.g., PACAP or BDNF agonists) that engage multiple signaling pathways. Antibody-based or peptide approaches offer inherent selectivity advantages over small molecules given GAP43's unique epitope regions.
Clinical Trials (5)
Relevant trials from ClinicalTrials.gov
By Phase
NA: 2 · PHASE1: 1 · PHASE4: 1 · Unknown: 1
Unknown
NCT06871839
n=120
Alzheimer's Disease, Lecanemab, Functional Magnetic Resonance Imaging
Interventions: Lecanemab treatment group, Conventional anti-dementia treatment gro
Sponsor: Cuibai Wei，Clinical Professor
NA
NCT05163626
n=200
Alzheimer Disease
Interventions: Combined aerobic exercise and cognitive
Sponsor: Xuanwu Hospital, Beijing
NA
NCT06726941
n=48
Ischemic Stroke, Acute, Acute Hemiparesis
Interventions: Physiotherapy and Rehabilitation Practic
Sponsor: Afyonkarahisar Health Sciences University
PHASE1
NCT03783416
n=72
Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Ixazomib (NINLARO®) capsules / Matching
Sponsor: Queen Mary University of London
PHASE4
NCT06131268
n=30
Major Depressive Disorder, Bipolar Affective Disorder, Currently De
Interventions: Venlafaxine
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico